AGP Executive Report
Last update: 4 hours agoHealth Technology: Siemens plans to send a healthcare delegation to Pakistan to pursue agreements on training and technology; the talks signal possible cooperation, not completed projects. Cancer Research: New ESMO data show durvalumab plus enfortumab vedotin improved event-free and overall survival in muscle-invasive bladder cancer patients unable or unwilling to receive cisplatin. Another study found apalutamide plus hormone therapy improved event-free survival in high-risk prostate cancer. Coverage Costs: Employer health plans are getting pricier: workers’ average annual contribution for family coverage rose 9% to $7,471, while average premiums reached $28,303, according to KFF. Drug Supply: Pakistan faces a shortage of imported rapid-acting insulin after a factory upgrade halted supplies; alternatives cost at least 20% more, while delayed price approvals have also disrupted access to essential medicines. Industry Growth: Ghana’s presidential candidate Mahamudu Bawumia discussed expanding local drug production and streamlining regulation with the Pharmaceutical Society of Ghana, pitching the country as a regional manufacturing hub.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
